Precision Optics Corporation, Inc. — Form 10-Q Summary
Business context and period: The company designs and manufactures optical instruments, primarily medical devices such as endoscopes, endocouplers, micro medical camera assemblies, and surgical visualization products; approximately 10% of its business is military and industrial products. This report covers the first quarter of fiscal 2013, the three months ended September 30, 2012, and compares results with the three months ended September 30, 2011.
Key financial results
| Metric | Quarter ended September 30, 2012 | Prior-year quarter |
|---|---|---|
| Revenue | $563,398 | $504,749 |
| Gross profit / margin | $129,473 / 23.0% | $139,294 / 27.6% |
| Operating loss | $356,844 | $263,202 |
| Net income (loss) | $(358,094) | $1,998,441 |
| Basic and diluted loss per share | $(0.27) | Basic $2.06; diluted $1.15 |
| Cash used in operating activities | $228,126 | $694,580 |
- Revenue increased 11.6%, mainly from higher sales of an advanced surgical visualization system used in spinal surgery, including a new product-line extension; lower micro-optics, endoscope, and endocoupler sales partly offset the increase.
- Gross margin declined to 23.0%. Management attributed the decrease to higher consulting costs, less favorable product mix, and nonrecurring manufacturing start-up expenses for new products.
- Research and development expense rose 37.1% to $207,291, primarily due to higher labor and materials costs. Selling, general and administrative expense rose 10.9% to $280,964, mainly due to consulting and insurance costs.
- The prior-year quarter’s net income included a $2,276,286 gain on the sale of patents to Intuitive Surgical. The current quarter had no comparable gain; therefore, the year-over-year net income comparison is substantially affected by this unusual prior-period item.
Financial position, liquidity, and financing
- At September 30, 2012, cash and cash equivalents were $2,337,694, current assets were $3,347,419, and current liabilities were $984,227. Cash was $145,923 at June 30, 2012.
- The company reported no outstanding 10% senior secured convertible notes at quarter-end. The remaining $50,000 principal held by one noteholder was exchanged for offering units, and accrued interest was paid. The cash flow statement separately reports $52,500 as payment of principal and interest; investors should verify how that cash-flow line reconciles with the note disclosure.
- A September 28 private placement raised $2.5 million gross through units priced at $0.90, comprising 2,777,795 common shares and warrants for 1,944,475 shares. The warrants have a $1.25 exercise price and a five-year term. Placement-agent warrants cover up to 194,446 shares at a $0.95 exercise price. Private-placement expenses of $29,556 had been paid and $242,137 remained unpaid at quarter-end.
- Financing activities provided $2,417,959 net cash during the quarter. The company used $228,126 in operating activities and reported $2,337,694 in ending cash.
- Contractual operating lease commitments after September 30, 2012 total $40,224; open purchase orders for fiscal 2013 were approximately $119,000. The company reported no off-balance-sheet arrangements and no default on indebtedness.
Outlook, risks, and other material matters
- Management expects operating losses to continue until sales reach breakeven and profitable levels. No quantified revenue, earnings, or cash-flow guidance is provided.
- Management cited approximately $1 million of orders for small endoscopes and approximately $250,000 of orders for micro medical camera assemblies received during the prior 12 months. Shipment timing and the resulting revenue are uncertain; management expected shipments against the camera-assembly orders to begin during fiscal 2013.
- The company is pursuing Microprecision optical components and camera assemblies, as well as handheld 3D endoscopes. Management described these markets as opportunities, while noting that product development, commercialization, regulatory requirements, competition, and unpredictable customer order timing create uncertainty.
- Customer concentration increased: the largest customer accounted for 54% of quarterly revenue, versus 14% a year earlier; the second-largest accounted for 21%, versus 32%. Management said customer concentration may fluctuate with the timing and size of orders.
- The September financing may trigger ownership-change limits on tax attributes. The company stated that, if triggered, the limits could restrict use of federal and state carryforwards to approximately $34,000 annually for 20 years.
- Management concluded that disclosure controls and internal control over financial reporting were not effective as of September 30, 2012. Reported material weaknesses include insufficient segregation of accounting duties and inventory valuation controls. The company described remediation steps but cautioned that it could not guarantee remediation.
- The company filed the resale registration statement on October 26, 2012, before the required filing deadline. The registration-rights agreement also provides for potential liquidated damages if effectiveness deadlines are missed, subject to its terms.
- The filing reports no known pending or threatened litigation expected to have a material impact and no material changes to the risk factors in the fiscal 2012 Form 10-K.
Important facts for investors to verify
- Reconcile the $52,500 cash-flow statement line for note principal and interest with the note disclosure describing principal exchanged for offering units and interest paid.
- Check the resale registration statement’s effectiveness and any related liquidated-damages exposure.
- Track conversion of the cited endoscope and camera-assembly orders into shipments, recognized revenue, collections, and gross margin.
- Monitor customer concentration, operating cash use, and whether the $2.5 million financing provides adequate runway as product-development costs continue.
- Assess progress in remediating the disclosed material weaknesses and the potential ownership-change limitation on tax-loss carryforwards.